Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management  by Trousse, Delphine et al.
S
c
m
D
C
a
Trousse et al General Thoracic Surgeryynchronous multiple primary lung cancer: An increasing
linical occurrence requiring multidisciplinary
anagement
elphine Trousse, MD,a Fabrice Barlesi, MD,b Anderson Loundou, PhD,c Anne Marie Tasei, MD,d
hristophe Doddoli, MD,a Roger Giudicelli, MD,a Philippe Astoul, MD, PhD,b Pierre Fuentes, MD,and Pascal Thomas, MD, FECTSa
O
o
r
c
M
s
a
a
y
R
t
b
a
o
m
e
p
v
p
o
i
a
a
C
s
O
w
a
S
c
r
t
a
t
G
TSEarn CME credits at
http://cme.ctsnetjournals.org
From the Departments of Thoracic Sur-
gery,a Thoracic Oncology,b and Pathology,d
Sainte Marguerite University Hospital; and
Department of Public Health and Biostatis-
tics,c Faculty of Medicine, Université de la
Méditerranée (Aix-Marseille II) and Assis-
tance Publique-Hôpitaux de Marseille, Mar-
seille, France.
Received for publication Sept 29, 2006;
revisions received Dec 16, 2006; accepted
for publication Jan 5, 2007.
Address for reprints: Pascal Thomas, MD,
FECTS, Department of Thoracic Surgery,
Ste Marguerite Hospital-CHU Sud, 270 Bd
Ste Marguerite, 13274 Marseille Cedex 9,
France (E-mail: pathomas@ap-hm.fr).
J Thorac Cardiovasc Surg 2007;133:1193-200
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgerym
doi:10.1016/j.jtcvs.2007.01.012
Tbjective: No guidelines detailing recommendations for the selection and treatment
f patients with synchronous multiple primary lung cancer have been published. We
eport on a single-institution experience with synchronous multiple primary lung
ancer, with emphasis on long-term survival.
ethods: We performed a retrospective study of 125 consecutive patients with
ynchronous multiple primary lung cancer who underwent operation between 1985
nd 2006. Various treatment strategies were applied, including perioperative ther-
py. Potential prognosticators were submitted to univariate and multivariate anal-
ses.
esults: Tumors were bilateral (n  34) or ipsilateral (n  91). Optimal surgical
reatment (complete anatomic resection with radical lymphadenectomy) was possi-
le in 65.6% of the cases. pN0 disease was present in 32.3% of the patients; 30-day
nd 90-day mortality rates were 4.5% and 11%, respectively. Two- and 5-year
verall survivals were 61.6% and 34%, respectively, with a median survival of 35
onths. On univariate analysis, smoking status, high Charlson index, low forced
xpiratory volume in 1 second, occurrence of postoperative complications, and
erformance of a pneumonectomy affected the overall survival adversely. Con-
ersely, bilateral disease, location in the same lobe, and pN0 disease were favorable
rognosticators. On multivariate analysis, low forced expiratory volume in 1 sec-
nd, nonoptimal surgical treatment, and performance of a pneumonectomy were
ndependent predictors of poor long-term survival, whereas female sex, younger
ge, asymptomatic disease, pN0 status, and performance of an adjuvant treatment
ffected the survival favorably.
onclusions: Provided there is an appropriate selection process, patients with
ynchronous multiple primary lung cancer are expected to benefit from surgery.
ptimal surgery should be performed, but pneumonectomy should be avoided
henever possible. Adjuvant treatment is suggested to provide an added survival
dvantage.
ynchronous multiple primary lung cancer (MPLC) is a presumed uncommon
entity, but its true incidence, ranging from 0.2% to 20%,1 is increasing as the
result of the widespread use of early detection tools such as multislice spiral
omputed tomography (CT), fluorescence endoscopy, and positron emission tomog-
aphy (PET) scanning. However, simultaneous tumors are ambiguously assessed by
he TNM staging system,2 which classifies this clinical situation either as a locally
dvanced disease when both tumors are located in a same lobe or as a metastatic
umor in the other cases. In the absence of easily available genetic or molecular
arkers, differentiation between MPLC and isolated pulmonary metastasis will
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1193
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G
TSemain difficult in the clinical setting, leading to controver-
ies regarding management considerations. There are cur-
ently no published guidelines detailing recommendations
or the selection and treatment of such patients. In a
anichean plan, two opposite strategies are faced: the belief
hat any resectable disease should be resected and the belief
hat surgery is a futile treatment for a potentially metastatic
ituation. From a pragmatic point of view, a multifocal
isease in the same lobe does not change the type of surgery
o be applied in most instances. Clearly, this is not the case
hen a pneumonectomy or a bilateral lung resection is
equired, showing evidence of some limitations regarding
he cardiopulmonary reserve. Conversely, patients with
on–small cell lung cancer (NSCLC) have a low chance to
ate of being cured by chemotherapy alone at any stage.
As proponents of a surgical approach within a multidis-
iplinary strategy, we aimed to report on our experience
ith synchronous MPLC, with emphasis on long-term
urvival.
aterials and Methods
etween July 1985 and May 2006, 125 consecutive patients un-
erwent operation with synchronous MPLC in a single academic
horacic surgery department among 2785 patients treated for a
rimary lung cancer during the period. Patients were identified by
creening a database in which any patient with an NSCLC was
ntered prospectively. Patients with typical carcinoid tumors or
ure bronchioloalveolar adenocarcinomas were not included in the
resent study. Tumors were defined as synchronous MPLC when
ultiple locations were discovered simultaneously (n  112) or
ithin a 24-month delay (n  13), provided that the second tumor
as ascertained retrospectively to be present at the time of the
reatment of the first tumor by reviewing the imaging files. Tumors
ere defined as MPLC when histology was different, when tumors
ere located in different segments of the same lobe, in different
obes, or bilaterally, and in the absence of evidence of an extratho-
acic disease. Tumors with satellite nodules (n  84), defined as
maller tumors (diameter  1 cm) located close to the original
ancer, in the same segment were not included in the study.
During the same period, 54 patients with metachronous primary
ung cancer were treated surgically at our institution.
atients
here were 27 women (21.6%) and 98 men (78.4%) aged from 40
Abbreviations and Acronyms
CI  confidence interval
CT  computed tomography
FEV1  forced expiratory volume in 1 second
NSCLC non–small cell lung cancer
MPLC multiple primary lung cancer
MRI magnetic resonance imaging
PET  positron emission tomographyo 80 years. The median age was 61.5 years (9.9 years). There a
194 The Journal of Thoracic and Cardiovascular Surgery ● Maere 91 patients (72.8%) with unilateral synchronous MPLC and
4 patients (27.2%) with bilateral synchronous MPLC. The Amer-
can Society of Anesthesiologists score was calculated for all
atients on the basis of their preoperative physical examination
esults. The mean score was 2  0.8, ranging from 1 (n  41) to
(n  2).
A total of 111 patients (88%) were smokers, and 14 patients
11%) were nonsmokers. Eighty patients (63%) smoked more than
0 packs/year. At the time of surgery, 60 patients (48%) were
urrent smokers.
Nineteen patients (15%) previously had an additional extratho-
acic malignancy (mean delay: 75.2 months) that was considered
n complete remission. Seven of them had a history of oropharyn-
eal carcinomas, and 4 of them had a history of lymphoma. The 8
ther patients were treated for various primary tumors.
Thirty-six patients (28%) had cardiovascular comorbidities.
hronic obstructive pulmonary disease was present in 48 patients
38%), according to the Global Initiative for Chronic Obstructive
ung Disease guidelines. The mean Charlson score was 2  1.7,
anging from 0 (n  11) to 9 (n  1).
The disease was discovered fortuitously (48.8%) or revealed by
ymptoms (51.2%).
reoperative Workup
ll patients underwent chest radiography, bronchoscopy, and chest
T scan including the upper abdomen (basic workup). An abnor-
al bronchoscopy was present in 33 cases (26.4%), and in 34
atients (27.2%) the histologic type of the tumors was known
efore surgery by the means of bronchoscopy or CT scan-guided
iopsies. The majority of patients (n 116; 93%) underwent brain
T scan. One supplementary patient underwent brain magnetic
esonance imaging (MRI). Routine bone scintigraphy was per-
ormed in 53 patients (42.4%). The last 12 patients of this series
ere explored with 18-fluorodeoxyglucose PET scanning (9.6%).
nvasive staging was performed in 7 patients with bilateral syn-
hronous MPLC; 5 (4%) underwent mediastinoscopy and 2 un-
erwent a thoracoscopy (1.6%). Extensive preoperative workup
as defined by the additional performance of routine brain CT
can or MRI, and bone scintigraphy or PET scanning to the basic
orkup. Such extensive preoperative workup was performed in 68
atients (54.4%): 27 patients (79.4%) in the bilateral group and 41
atients (45%) in the unilateral group. The treatment strategy was
ecided at the occasion of the institutional oncologic multidisci-
linary meeting.
urgery
henever possible, an anatomic resection (ie, lobectomy or pneu-
onectomy) was performed for the 2 tumors, together with an
psilateral lymphadenectomy, and was considered as an optimal sur-
ery. Sublobar resections (ie, wedge or segmentectomy) and lymph
ode sampling were regarded as nonoptimal procedures. Lymphade-
ectomy was defined by the harvesting of at least 10 lymph nodes and
he removal of two or more ipsilateral mediastinal stations.3 When
oth criteria were not satisfied at the reading of the pathology report,
he N status was graded as pNx.
Neoadjuvant treatment included any chemotherapy regimen
iven before surgery or between the two surgical sessions, when
pplicable in case of bilateral disease.
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G
TSathologic Staging
athologic staging was based on the International System for
taging Lung Cancer.2 A total of 123 patients had 2 cancers
unilateral tumors in 89 and bilateral tumors in 34). Among the
nilateral group, 62 tumors were in the same lobe and 27 tumors
ere in a different lobe. Two patients had 3 unilateral lung
arcinomas, in the same lobe in 1 patient and in a different lobe in
patients.
Histology was identical in 104 cases (83.2%). Adenocarcinoma
nd squamous cell carcinoma were the predominant histologic
ypes, 52% and 28.8%, respectively, in this group. Histology was
ifferent in (n  12) in the bilateral group and (n  9) unilateral
roup. Large cell carcinomas accounted for 8.8% of the cases.
There were 62 patients (49.6%) classified with pM1 pulmonary
nd 63 patients (50.4%) classified with pT4 for multifocal tumors
n the same lobe.2 In the group classified with pM1 pulmonary, 28
atients (45.2%) had ipsilateral cancers in a different lobe and 34
atients (54.8%) had bilateral cancers. Among patients with bilat-
ral cancers, 11 (32.3%) had pN0 for 1 side and pNx for the other
ide, 5 (14.7%) had at least 1 side with lymph node invasion
pN), 11 (32.3%) had pN0 bilaterally, and 7 (20.6%) had pNx for
oth sides. Among the ipsilateral group, 33 patients (36.2% of this
roup) had a pN0 disease, 32 patients (35.2%) had a pN2 disease,
7 patients (18.7%) had a pN1 disease, and 9 patients (9.9%) had
pNx disease.
tatistics
he statistical analysis was performed by using the Statistical
ackage for the Social Sciences version 13.0 software package
SPSS Inc, Chicago, Ill). Quantitative variables were expressed as
ean  standard deviation. For all patients, survival was calcu-
ated from the date of surgery until the date of last follow-up if the
atient was still alive on May 31, 2006, or the date of death
ollected by consulting the City Hall registry. Survivorship was
alculated according to the Kaplan–Meier method, including the
perative mortality. Differences in survival were tested for signif-
cance by the log-rank test. A Cox proportional hazards model was
t to examine and adjust for any explanatory variables. Forward
tepwise procedure was used to select the variables with the
reatest prognostic value (P  .05).
esults
urgery
hree patients with a bilateral disease had only one side
urgically explored because of substantial postoperative
omplication or insufficient pulmonary reserve preventing a
ilateral resection. An additive treatment (chemotherapy
nd/or radiotherapy) was performed in these 3 cases.
mong the 31 patients with a bilateral disease who under-
ent operation on both sides, 2 were treated during the same
ession and 29 were treated sequentially with a median
elay of 5.7 months.
The details of the surgical procedures are given in Table 1.
adical lymphadenectomy was performed in 94 patients
75.2%), and lymph node sampling was performed in 31
atients (24.8%). A mean of 3.5 (1-8) nodal stations and
3.3 (11.4) lymph nodes were explored at first surgery, h
The Journal of Thoracicnd 2.7 (1–11) nodal stations and 8.3 (9.2) lymph nodes
ere explored at the second surgery. In total, 82 patients
65.6%) underwent an optimal surgical treatment and 43
atients (34.4%) received limited resections because of the
resence of comorbidity or poor performance status.
reatment Strategy
ixty-three patients (50.4%) underwent surgery alone.
Neoadjuvant platin-based chemotherapy was applied in
9 patients (15.2%): 2 cycles in 13 patients, 3 cycles in 2
atients, and 4 cycles in 4 patients.
Adjuvant treatment consisted of chemotherapy or radio-
herapy or both and was administered to 62 patients
49.6%). Fifty-six patients (44.8%) received 2 to 5 sessions
f adjuvant platin-based chemotherapy (mean: 3 sessions).
wenty-three patients (18.4%) underwent adjuvant radio-
herapy. Eighteen patients (14.4%) underwent chemoradio-
herapy. Three patients (2.4%) who died after surgery could
ot receive the foreseen adjuvant treatment. Finally, 66
atients (52.8%) received a local treatment only (surgery
ossibly associated with radiotherapy), and 59 patients
47.2%) received an additional systemic treatment.
ostoperative Course and Long-term Survival
hirty-four patients (27.2%) had postoperative complica-
ions. Sputum retention was the most frequent (8.8%), fol-
owed by pneumonia (6.4%) and bronchial fistula (1.6%).
he 30-day mortality rate (n  6) was 4.5% (95% confi-
ence interval [CI]: 1.75-9.9). Causes of death were bron-
hial fistula, acute respiratory distress syndrome, cardiac
ailure, and multiple organ failure. The overall 90-day mor-
ality rate (n  14) was 11% (95% CI: 6.16-17.8). Mean
ABLE 1. Surgical procedures for synchronous multiple
rimary lung cancer (n  125 patients)
No. of
patients %
urgical procedure for unilateral MPLC 91 72.8
ublobar resection 14 11.2
Bi)lobectomy 34 27.2
xtended lobectomy* 3 2.4
neumonectomy 40 32
urgical procedure for bilateral MPLC 34 27.2
ublobar and abstention 1 0.8
obectomy and abstention 2 1.6
ilateral sublobar resection 6 4.8
obectomy and sublobar resection 14 11.2
xtended lobectomy and sublobar resection 1 0.8
ilateral lobectomy 7 5.6
xtended lobectomy and lobectomy 2 1.6
neumonectomy and sublobar resection 1 0.8
Extended lobectomy : bronchial and/or vascular sleeve lobectomy.ospitalization stay was 17 days.
and Cardiovascular Surgery ● Volume 133, Number 5 1195
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G
TSMean duration of follow-up was 57.2 months (95% CI:
5.2-69.2). Fourteen patients (11.2%) were lost to follow-
p. At last follow-up, 83 patients (66.4%) were dead and 42
atients (33.6%) were still alive. The overall 2- and 5-year
urvivals were 61.6% (95% CI: 52.6-70.6) and 34% (95%
I: 24.8-43.2), respectively. Median survival was 34.9
onths (95% CI: 21.7-48.1). The overall 10-year survival
as 19% (95% CI: 10.1-27.9) (Figure 1).
Forty-nine patients (38.6%) experienced recurrence
ithin a mean delay of 9.3 months (median: 4.4 months).
he lung was the site of first recurrence in 40.8% of the
ases, followed by multifocal (30.6%), brain (22.4%), bone
4.1%), and liver (2%) sites. Disease-free survivals were
0% (95% CI: 50.1–70.1) at 2 years, 56% (95% CI: 45.2–
6.8) at 5 years, and 51% (95% CI: 38.1–64.6) at 10 years.
igure 1. Overall survival of 125 patients with synchronous MPLC.
PLC, multiple primary lung cancer.196 The Journal of Thoracic and Cardiovascular Surgery ● MaNo significant difference in 5-year survival was observed
etween patients who received a local treatment only and
atients who also received chemotherapy (52.8% vs 47.2%,
 .58).
On univariate analysis, patients with a bilateral disease
ad a better survival than those with a unilateral disease
P  .025). Unilateral disease in the same lobe was also
ssociated with a better outcome than in a different lobe
 P  .033) (Figure 2). The following continuous vari-
bles appeared as prognostic parameters (Table 2): Charl-
on index, forced expiratory volume in 1 second (FEV1)
percentage), and FEV1/forced vital capacity (percent-
ge). Current smokers had an impaired survival, as well
s patients who underwent a pneumonectomy. The lymph
ode status significantly affected survival: The best over-
ll survival was observed for patients with a pN0 disease
51.4%; 95% CI: 16.6-86.1) compared with those with a
N disease (15.4%; 95% CI: 7.8-23.1), whereas pa-
ients with a pNx disease (42.5%; 95% CI: 28.3-56.8) had
n intermediate prognosis (P  .01) (Figure 3).
Cox’s multivariate regression model identified the fol-
owing variables as independent adverse prognosticators of
verall survival (Table 3): male sex, patient age more than
0 years, symptomatic disease, low FEV1 (%), performance
f a pneumonectomy, absence of an adjuvant therapy, ab-
ence of an optimal surgical resection, and presence of
ymph node metastasis. Table 4 details the variables that did
ot enter the model at the last step of the analysis.
iscussion
ccording to the literature, MPLC occurs with an incidence
f 0.2% to 20%,1,4-6 when referring to the definition criteria
f Martini and Melamed.7 However, these criteria are not
asily applicable in the case of synchronous MPLC, a clin-
cal entity not recognized by the International Union
gainst Cancer TNM classification, which scales this con-
Figure 2. Overall survival according to tu-
mor location.y 2007
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G
TSition in “nonsurgical” stages (IIIB and IV).8 With the use
f more realistic criteria, the incidence of synchronous
PLC was 4.5% in our experience. Given the high preva-
ence of benign nodules detected at the occasion of the
reoperative workup in patients with lung cancer, and the
nconsistency of predictions based on CT features, there is
need for improving diagnostic accuracy of synchronous
PLC to avoid overlooking a possible curative treatment
or the patient.9,10 A different histology in two obviously
istinguishable lung tumors is a strong argument in favor of
he primary nature of both diseases. However, this situation
s rare, occurring in approximately 15% of cases, in our
xperience. In the case of similar histologic conditions, to
ifferentiate a pulmonary metastasis from a true synchro-
ous lung cancer is difficult in the absence of genetic and
ABLE 2. Results of a univariate analysis for prognostic
actors negatively affecting overall survival in 125 patients
ith synchronous multiple primary lung cancer
ariables No. P value
ex (M/F) 98/27 .30
ge (60 y) 50/75 .15
ilateral vs unilateral 34/91 .02
ilateral vs same lobe vs different lobe 34/63/28 .03
ymptomatic disease (Y/N) 64/61 .11
ast/current smokers 65/60 .01
obacco (40 packs/y) 40/85 .74
SA score (1 and 2 vs 3 and 4) 89/36 .32
YHA classification (1 and 2 vs 3) 109/16 .17
OPD (Y/N) 47/72 .09
EV1 (L) — .12
EV1 (%) — .002
EV1/FVC (%) — .008
ardiovascular comorbidity (Y/N) 35/90 .83
istory of other cancers (Y/N) 18/107 .72
harlson index — .05
xtensive preoperative workup (Y/N) 66/59 .23
reoperative histology (Y/N) 33/92 .22
ptimal surgery (Y/N) 82/43 .34
ymphadenectomy (Y/N) 94/31 .41
neumonectomy (Y/N) 41/89 <104
ifferent histology (Y/N) 21/104 .82
DK vs other histology 64/61 .36
4 vs M1 63/62 .56
N0 vs pNx vs pN 44/27/54 .01
T main tumor vs pT other tumor(s) .58
ostoperative complications (Y/N) 34/91 .07
eoadjuvant therapy (Y/N) 19/106 .65
djuvant treatment (Y/N) 58/67 .43
ocal vs systemic treatment 66/59 .58
SA, American Society of Anesthesiologists; NYHA, New York Heart
ssociation; COPD, chronic obstructive pulmonary disease; FEV1, forced
xpiratory volume in 1 second; FVC, forced vital capacity; ADK, adenocar-
inoma. Statistically significant variables in bold.olecular analysis, not available in routine clinical practice. C
The Journal of Thoracict is also difficult to discriminate between synchronous
PLC and multiple lung metastases from an occult distant
ancer. A definitive proof of the malignancy of all suspi-
ious lung nodules is critical and should be obtained before
efining the optimal treatment.11
Searching for distant metastases or confirming complete
emission of a previous extrathoracic neoplasm is cru-
ial.11-15 Brain MRI, fluorescence bronchoscopy, and
hole-body 18-fluorodeoxyglucose PET scanning added
aluable contributions to the noninvasive staging of lung
ancer. The accuracy of brain MRI in diagnosing brain
etastases is definitely higher than that of brain CT scan.
luorescence bronchoscopy was proven to improve the de-
ection of concomitant central premalignant lesions or syn-
hronous invasive lung cancers. PET also carries higher
ensitivity and specificity than does CT scanning for local
egional staging, detection of occult liver or adrenal metas-
ases, and disclosure of incidental coexistent neoplasms. We
Figure 3. Overall survival according to lymph node status (pN).
ABLE 3. Results of a multivariate analysis for prognostic
actors negatively affecting survival in 125 patients with
ynchronous multiple primary lung cancer
ariable No.
Hazard
ratios 95% CI P value
ex (male) 98 2.5 1.15–5.42 .021
ge (60 y) 75 0.53 0.31–0.91 .022
symptomatic (yes vs no) 61 0.42 0.24–0.72 .002
EV1 (%) 119 0.95 0.93–0.98 .0001
neumonectomy (yes vs no) 41 6.6 3.34–13.1 .0001
ptimal surgery (no vs yes) 43 2.3 1.14–4.75 .02
djuvant treatment (no vs yes) 67 1.8 1.02–3.33 .043
N0 disease (no vs yes) 44 2.9 1.2–6.9 .004I, Confidence interval; FEV1, forced expiratory volume in 1 second.
and Cardiovascular Surgery ● Volume 133, Number 5 1197
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1
G
TSailed to ascribe any prognostic impact to an “extensive”
reoperative workup in comparison with a “basic” workup,
ecause modalities of such extensive workup changed along
he period according to evolving accessible technologies.
n extensive preoperative workup was performed in more
han three-fourths of the patients with bilateral synchronous
PLC, but in less than one-half of patients with unilateral
ynchronous MPLC. Accordingly, invasive preoperative
taging was performed only in the former subset of patients
o rule out mediastinal lymph node metastasis.9,11 The bi-
ateral location of the disease was identified as a favorable
rognosticator on univariate analysis.
Bilateral MPLC is usually approached through two dis-
inct thoracotomies, even if sternotomy may offer an ade-
uate exposure for lung resections and extended bilateral
ediastinal lymphadenectomy.16-24 In the majority of our
atients, we favored a staged bilateral thoracotomy to re-
uce postoperative morbidity.23 In the eventuality of bilat-
ral tumors of markedly different stages, we favored the
reatment of the earliest tumor first, which usually required
he lesser lung sacrifice, to preserve the feasibility and
afety of a contralateral resection. This sequence may also
e chosen when the histology of the smallest tumor is
nknown and/or its primary nature remains uncertain. In
hat case, a limited resection is performed as a staging
rocedure, usually by video-assisted thoracoscopy. Limited
esection on a single lung after contralateral pneumonec-
omy was performed in 1 patient. However, this situation is
ot comfortable technically and may result in severe com-
lications—thus, it is not recommended.
Our results clearly show that performance of a pneumo-
ectomy had a major adverse and independent impact on
urvival. The risk of death is well characterized by the
ABLE 4. Scores at the last step of an analysis of overall
urvival for other relevant covariates excluded from the
ox model
ariables Scores P value
obacco 40 packs/y 0.58 .45
YHA (1 and 2 vs 3) 2.07 .15
bsence of cardiovascular comorbidity 0.05 .82
EV1/FVC (%) 0.008 .93
bsence of COPD 0.016 .90
harlson index 0.30 .58
bsence of extensive preoperative workup 0.008 .93
bsence of neoadjuvant therapy 0.03 .86
ilateral vs same lobe vs different lobe 0.98 .61
T status 2.40 .12
bsence of postoperative complications 0.23 .63
OPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory
olume in 1 second; FVC, forced vital capacity; NYHA, New York Heart
ssociation.ttached 6.6 hazard ratio. Explanations are multiple: en- i
198 The Journal of Thoracic and Cardiovascular Surgery ● Maanced postoperative morbidity and mortality, impaired car-
iopulmonary reserve, and higher staged disease. Of note,
uch a deleterious effect of pneumonectomy has been al-
eady reported for early12-14 and advanced stages.15
Consequently, pneumonectomy should probably be
voided whenever possible, even for ipsilateral tumors lo-
ated in different lobes. Alternative lung-sparing resec-
ions are also to be considered in the light of the residual
ulmonary function, because, as we disclosed, FEV1
ercentage is an independent prognosticator of long-term
urvival.
As previously suggested,18 the overall prognosis of our
atients with synchronous MPLC was poorer than that of
hose with a localized disease. To date, no standard treat-
ent exists and few guidelines focus on the management of
ynchronous MPLC.16 We took great care to reduce possi-
le bias in interpreting the results: exclusion of histologic
ypes associated with a favorable behavior, that is, typical
arcinoid and pure bronchioloalveolar adenocarcinoma, and
xclusion of tumors with satellite nodules whose prognosis
s now well defined. Conversely, we included those patients
ith multiple tumors and invaded nodes in common lym-
hatic pathways to comply with real-life patients, contrary
o one of the criteria from Martini and Melamed.7 This last
oint is of paramount importance because the pN status
eavily influences the final results, as we showed in the
resent study (hazard ratio of 2.9) and as reported by
thers.16-18 Indeed, most of the published articles on the
opic included many of these possible causes of confu-
ion.1,4,10,17-20 We observed 5- and 10-year overall sur-
ivals of 34% and 19%, respectively, that compare fa-
orably with published data (0%–33% and 0%–14%,
espectively).1,6,10,21-24 Survival was also far better than
hat of a metastatic disease: 10% to 23% 5-year survival
or patients with a resectable NSCLC and a single syn-
hronous brain or adrenal metastasis managed surgically,
n keeping with the most optimistic reports.16 Finally, the
ap we observed between overall survival and disease-
ree survival also shows that non– cancer-related deaths
eighed considerably in the outcome of our patients.
onsequently, we found a prognostic significance to the
harlson index on univariate analysis, as did other au-
hors in publications involving earlier stages.25
Some powerful prognostic variables on univariate anal-
sis lost their significance at multivariate analysis. The
etter survival observed in patients with a bilateral disease
ay be partly explained by a selection bias because of a
ore extensive preoperative workup to rule out any ex-
rathoracic disease and identify fit candidates for a bilateral
urgery. The worse survival observed in those patients with
ultiple ipsilateral tumors in different lobes might reflect
he fact that they underwent a pneumonectomy in most
nstances. The intermediate survival noted in patients with
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TSultifocal tumors in the same lobe is probably the end result
f a balanced risk/benefit ratio in which the risks of a
urgical management were not increased when compared
ith those of a localized disease because the type of surgery
o be applied did not differ, and the long-term outcome was
mpaired because some of those situations included true
etastatic conditions.
Overall long-term outcome was affected individually by
ariables linked to the patient, the disease, and the treat-
ent. The present study adds new information on the topic,
ecause we have identified some independent prognostic
haracteristics that may improve the management of such
atients. Optimal surgery was defined in line with evidence-
ased surgical principles for the treatment of early-stage
SCLC, according to which at least a lobectomy and medias-
inal lymphadenectomy should be performed.26 Our results
trongly suggest that such principles should also be applied in
he context of synchronous MPLC. A clear limitation, how-
ver, is the functional reserve of surgical candidates, especially
hen tumors are located in different lobes or lungs. However,
here is growing evidence that an anatomic segmentectomy
ogether with mediastinal lymphadenectomy may provide
ong-term survival similar to that associated with lobectomy in
atients with peripheral tumors of less than 3 cm of greater
ize, at a lower risk, and with a lower functional impairment. 27
We failed to identify any obvious divergence of outcome
n patients having received any form of systemic treatment
n addition to surgery when compared with that of those
ho received a local treatment only—that is, surgery or
urgery plus adjuvant radiotherapy. One may point out that
oo many treatment options and drug regimens were applied
uring the period, precluding sufficiently sized groups for
omparison. In addition, the accumulated toxicity of neo-
djuvant chemotherapy and surgery, particularly when a
ilateral surgery was required, might have resulted in sub-
tantial morbidity and inability of the patient to tolerate a
ull course of chemotherapy postoperatively. Nevertheless,
pproximately 40% of the patients in the present series
ould receive 3 cycles of adjuvant platin-based chemother-
py, and this strategy was identified as an independent
redictor of improved survival by multivariate analysis.
his observation is in agreement with current recommen-
ations for the treatment of early-stage NSCLC based on
eta-analysis of randomized studies that demonstrated a
urvival benefit of adjuvant chemotherapy in resected stages
I to IIIA NSCLC.28
onclusions
he present study demonstrates that synchronous MPLC is
n increasing clinical reality, the prognosis of which seems
orse than that of a localized disease but far better than that
f an advanced disease. The pretreatment workup of pa-
ients with multiple lung tumors should exclude any ex-
The Journal of Thoracicrathoracic disease and select fit candidates for a multidis-
iplinary management. Provided that prerequisite is met, the
ypothesis of synchronous MPLC should prevail on that of
metastatic disease, and, in turn, surgery should be kept in
he treatment plan. Accordingly, a lobectomy associated
ith lymphadenectomy and followed by adjuvant chemo-
herapy seems to confer substantial long-term survival at a
ow risk. Pneumonectomy should be avoided, and alterna-
ive lung-sparing resections should be considered whenever
ossible. This singular condition typifies the need for mul-
idisciplinary meetings defining the management of any
ndividual patient.
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